Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 99 Carcinoma, Hepatocellular 57 Breast Neoplasms 41 Neoplasms 40 Small Cell Lung Carcinoma 39 Lung Neoplasms 34 Triple Negative Breast Neoplasms 32 Colorectal Neoplasms 31 Urinary Bladder Neoplasms 29 Melanoma 28 Neoplasm Metastasis 27 Carcinoma, Transitional Cell 26 Carcinoma, Renal Cell 21 Ovarian Neoplasms 18 Stomach Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 14 Head and Neck Neoplasms 14 Uterine Cervical Neoplasms 13 Liver Neoplasms 11 Recurrence 10 Prostatic Neoplasms 10 Lymphoma 9 Glioblastoma 9 Solid Tumors 8 Sarcoma 8 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Carcinoma, Merkel Cell 7 Solid Tumor 6 Rectal Neoplasms 6

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡